Regulations.gov document
Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent…
Notice · FDA-1999-D-0081 · posted Jan 30, 2020
Key facts
| Document ID | FDA-1999-D-0081-0051 |
|---|---|
| Title | Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-1999-D-0081 |
| Posted | Jan 30, 2020 |
| Federal Register citation | 85 FR 5448 |
| FR document number | 2020-01700 |
| Comment period opens | Jan 30, 2020 |
| Effective date | Jan 30, 2020 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: